124 related articles for article (PubMed ID: 26167454)
1. Determination of Maximum Tolerated Dose and Toxicity of Inauhzin in Mice.
Zhang Q; Zeng SX; Lu H
Toxicol Rep; 2015; 2():546-554. PubMed ID: 26167454
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle encapsulation of non-genotoxic p53 activator Inauhzin-C for improved therapeutic efficacy.
Bhattarai N; Wang J; Nguyen D; Yang X; Helmers L; Paruch J; Li L; Zhang Y; Meng K; Wang A; Jayawickramarajah J; Wang B; Zeng S; Lu H
Theranostics; 2021; 11(14):7005-7017. PubMed ID: 34093867
[TBL] [Abstract][Full Text] [Related]
3. Inauhzin(c) inactivates c-Myc independently of p53.
Jung JH; Liao JM; Zhang Q; Zeng S; Nguyen D; Hao Q; Zhou X; Cao B; Kim SH; Lu H
Cancer Biol Ther; 2015; 16(3):412-9. PubMed ID: 25692307
[TBL] [Abstract][Full Text] [Related]
4. Structure and activity analysis of Inauhzin analogs as novel antitumor compounds that induce p53 and inhibit cell growth.
Zhang Q; Ding D; Zeng SX; Ye QZ; Lu H
PLoS One; 2012; 7(10):e46294. PubMed ID: 23115626
[TBL] [Abstract][Full Text] [Related]
5. Global effect of inauhzin on human p53-responsive transcriptome.
Liao JM; Zeng SX; Zhou X; Lu H
PLoS One; 2012; 7(12):e52172. PubMed ID: 23284922
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
[TBL] [Abstract][Full Text] [Related]
7. Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat.
Brown AP; Morrissey RL; Faircloth GT; Levine BS
Cancer Chemother Pharmacol; 2002 Oct; 50(4):333-40. PubMed ID: 12357309
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).
Giovanella BC; Stehlin JS; Hinz HR; Kozielski AJ; Harris NJ; Vardeman DM
Int J Oncol; 2002 Jan; 20(1):81-8. PubMed ID: 11743646
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.
Jia L; Gorman GS; Coward LU; Noker PE; McCormick D; Horn TL; Harder JB; Muzzio M; Prabhakar B; Ganesh B; Das Gupta TK; Beattie CW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):513-24. PubMed ID: 21085965
[TBL] [Abstract][Full Text] [Related]
11. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
Kratz F; Ehling G; Kauffmann HM; Unger C
Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome.
Mirsalis JC; Schindler-Horvat J; Hill JR; Green CE; Mitoma C; Tomaszewski JE; Tyson CA; Donohue SJ
Cancer Chemother Pharmacol; 2003 Mar; 51(3):193-201. PubMed ID: 12655436
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
Marshall JL; Wellstein A; Rae J; DeLap RJ; Phipps K; Hanfelt J; Yunmbam MK; Sun JX; Duchin KL; Hawkins MJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2347-54. PubMed ID: 9815633
[TBL] [Abstract][Full Text] [Related]
17. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision.
Mick R; Ratain MJ
J Natl Cancer Inst; 1993 Feb; 85(3):217-23. PubMed ID: 8423626
[TBL] [Abstract][Full Text] [Related]
18. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
[TBL] [Abstract][Full Text] [Related]
19. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
20. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.
Lissitchkov T; Arnaudov G; Peytchev D; Merkle Kh
J Cancer Res Clin Oncol; 2006 Feb; 132(2):99-104. PubMed ID: 16292542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]